EGFR and non-small cell lung carcinoma: To elucidate the molecular mechanisms of action of theasinensin A in conjunction with nimotuzumab in wild-type EGFR NSCLC, we examined whether drug-mediated modulation of EGFR signaling, including activation of STAT3 and ERK, is implicated in progression of NSCLC.